A phase 2 study of S-337395 to assess the efficacy and safety
Latest Information Update: 23 Dec 2024
Price :
$35 *
At a glance
- Drugs S-337395 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2024 New trial record